News|Articles|March 6, 2026

AJMC® in the Press, March 6, 2026

Listen

0:00 / 0:00

Key Takeaways

Coverage denials and prior authorization delays can compromise timely treatment, creating clinical deterioration and compounding financial toxicity as care escalates.
Broadened semaglutide eligibility signals substantial demand, while payer coverage limitations and drug pricing remain central constraints on real-world uptake.
CRC risk mitigation is strengthened by symptom awareness, timely diagnostic evaluation, and adherence to prevention strategies as younger-onset incidence continues rising.
An independent coalition of autism researchers and advocates is organizing to preserve scientific rigor and continuity in federal advisory processes amid leadership restructuring.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article from the Sparta Independent referenced a feature published on AJMC.com, the website of The American Journal of Managed Care^® (AJMC^®). The article, “How Insurance Claim Denials Harm Patients’ Health, Finances,” focused on how delays in receiving coverage for essential medication, including through insurance claim denials, can hinder treating patients, especially as symptoms worsen and costs increase.

An AJMC.com article titled “Semaglutide Eligibility Expands to Over Half of US Adults” was referenced in an article from The Healthy. The former highlighted semaglutide’s potential benefits in the US for weight loss and diabetes, though access and cost concerns were prevalent.

An article from Healthandme referenced a Q&A published on AJMC.com. The Q&A, “3 Pillars of CRC Prevention Can Curb Rising Mortality: Jordan Karlitz, MD,” featured Karlitz discussing how younger patients could identify symptoms before more issues could occur, especially as the incidence of colorectal cancer rises in younger populations.

An article from AJMC.com, “Autism Research Leaders Launch Independent Committee to Counter RFK’s Panel,” was referenced in an article by Tag24. The AJMC.com piece discussed the formation of an independent coordinating body formed of leading autism researchers and advocates that is aiming to counter recent changes to the Interagency Autism Coordinating Committee overseen by HHS.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

Pirtobrutinib’s first-line approval in chronic lymphocytic leukemia or small lymphocytic leukemia was based on data from the BRUIN CLL-313 trial. | Image credit: jittawit21 - stock.adobe.com

October 2nd, 2026

FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion

This moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Michael S. Barr, MD< MBA, MACP, FRCP | Image Credit: © MEDIC LLS

October 2nd, 2026

VBC Risk Is Outpacing Provider Readiness, CMS Must Act

CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.

Sjogren's Syndrome text with Medical Stethoscope on wooden background | Image credit may1985 - stock.adobe.com

October 2nd, 2026

Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

globe | Image credit: Who is Danny - stock.adobe.com

October 2nd, 2026

Nickel, Fragrance Top Sensitizers in Patients With Hand Eczema

Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.